Elicio Therapeutics Inc(ELTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 8:25 AM ET (Korea 10/30 21:25)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.11 | Insider Own | 27.95% | Shs Outstand | 21.9M | Perf Week | -9.79% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 10.13% | Insider Trans | - | Shs Float | 19.5M | Perf Month | -3.85% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.48 | Inst Own | 20.09% | Short Float | 8.72% | Perf Quarter | -37.5% |
| Income | -0.04B | P/S | - | EPS this Y | 27.07% | Inst Trans | 16.33% | Short Ratio | 5.43 | Perf Half Y | -83.52% |
| Sales | 0.00B | P/B | 4.83 | EPS next 5Y | 22.95% | ROA | -124.36% | Short Interest | 1.70M | Perf YTD | -78.02% |
| Book/sh | 0.36 | P/C | 2.02 | EPS past 3/5Y | 85.75% 37.53% | ROE | -774.56% | 52W High | -89.06% ($16.00) | Perf Year | -81.38% |
| Cash/sh | 0.87 | P/FCF | - | Sales past 3/5Y | - | ROIC | -180.09% | 52W Low | 21.53% ($1.44) | Perf 3Y | -72.66% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 49.43% | Gross Margin | - | Volatility(W/M) | 11.96% 9.59% | Perf 5Y | -95.8% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.77 | EPS Q/Q | 35.07% | Profit Margin | - | RSI (14) | 44.02 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.77 | Sales Q/Q | - | SMA20 | -2.26% ($1.79) | Beta | 1.64 | Target Price | $14.38 |
| Payout | - | Debt/Eq | 1.78 | Earnings | 2026/8/13 | SMA50 | -16.24% ($2.09) | Rel Volume | 0.43 | Prev Close | $1.85 |
| Employees | 33 | LT Debt/Eq | 1.65 | EPS/Sales Surpr. | 20% - | SMA200 | -74.32% ($6.81) | Avg Volume(3M) | 0.31M | Price | $1.75 |
| IPO | 2021/2/5 | Option/Short | Yes/Yes | Trades | 848 | Volume | 135,957 | Change | -5.41% |
🧬 Elucidio Therapeutics is a clinical-stage biotech company developing immuno-oncology therapeutics based on its proprietary Amphiphile platform. By targeting lymph nodes to amplify immune responses, the company is clinically evaluating its candidate drugs against hard-to-treat solid tumors, including KRAS mutation-positive pancreatic and colorectal cancers.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
ELTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +27.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #422 of 594 in the industry
Based on market cap of $47M.
MREO#418 Mereo Biopharma Group Plc ADR $48M PER - 
ATNM#419 Actinium Pharmaceuticals Inc $48M PER 4.3 
SER#420 Serina Therapeutics Inc $48M PER - 
CRBU#421 Caribou Biosciences Inc $48M PER - ELTX#422 Elicio Therapeutics Inc $47M PER - 
FAQ
What kind of company is ELTX?
ELTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ELTX?
The market cap of ELTX is approximately $47M, ranking 4,880 within its sector.
What is the 52-week high and low for ELTX?
ELTX has recorded a 52-week high of $16.00 and a low of $1.44.
